BioMarin Pharma falls after lowering annual forecast

** Shares of BioMarin Pharmaceutical BMRN.O fall 6.9% to $53.50 in extended trading

** Drugmaker cuts its 2026 profit per share forecast to a range of $2.80 to $3.10 compared with its prior range between $4.90 and $5.10

** BMRN expects its 2026 annual sales forecast in the range of $3.80 billion to $3.90 billion versus its prior outlook between $3.875 billion and $3.925 billion

** Company says revenue forecast was updated to reflect uncertainty around the timing of multiple orders from a single international customer

** Expects the Alesta acquisition and BMN 450 licensing deal to result in pre-tax charges of about $320 million and $83 million, respectively, in 2026, reducing EPS by about $1.55 and 32 cents

** BMRN posts Q3 revenue of $1.025 billion compared to analysts' estimate of $1.026 billion - LSEG data

** Q3 sales of genetic disorder drug Voxzogo came in at $245 million vs estimates of $257 million

** As of last close, stock down 3.3% YTD